Pharma Mar (PHM) Aperçu de l'action
Pharma Mar, S.A., société biopharmaceutique, se consacre à la recherche, au développement, à la production et à la commercialisation de principes bioactifs destinés à l'oncologie en Espagne, en Italie, en Allemagne, en Irlande, en France, dans le reste de l'Union européenne, aux États-Unis et dans le reste du monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 5/6 |
| Performances passées | 5/6 |
| Santé financière | 6/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
PHM Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharma Mar, S.A. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €78.40 |
| Plus haut sur 52 semaines | €105.20 |
| Plus bas sur 52 semaines | €64.00 |
| Bêta | 0.43 |
| Variation sur 1 mois | -0.51% |
| Variation sur 3 mois | -21.83% |
| Variation sur 1 an | -0.89% |
| Variation sur 3 ans | 131.68% |
| Variation sur 5 ans | 11.84% |
| Évolution depuis l'introduction en bourse | 65.40% |
Nouvelles et mises à jour récentes
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...
PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.Recent updates
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Rendement pour les actionnaires
| PHM | ES Biotechs | ES Marché | |
|---|---|---|---|
| 7D | -0.8% | 2.1% | 1.7% |
| 1Y | -0.9% | 23.3% | 32.3% |
Rendement vs Industrie: PHM a sous-performé le secteur Spanish Biotechs qui a rapporté 23.3 % au cours de l'année écoulée.
Rendement vs marché: PHM a sous-performé le marché Spanish qui a rapporté 32.3 % au cours de l'année écoulée.
Volatilité des prix
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.6% |
Cours de l'action stable: Le cours de l'action de PHM a été volatil au cours des 3 derniers mois par rapport au marché Spanish.
Volatilité au fil du temps: La volatilité hebdomadaire de PHM ( 8% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Spanish.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1986 | 505 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., société biopharmaceutique, se consacre à la recherche, au développement, à la production et à la commercialisation de principes bioactifs destinés à l'oncologie en Espagne, en Italie, en Allemagne, en Irlande, en France, dans le reste de l'Union européenne, aux États-Unis et dans le reste du monde. La société exerce ses activités dans les secteurs de l'oncologie et de l'interférence ARN. Elle développe et commercialise Yondelis pour le traitement du sarcome des tissus mous et du cancer de l'ovaire, Aplidin pour le traitement du myélome multiple R/R et Zepzelca pour le traitement des patients atteints de cancer du poumon à petites cellules.
Pharma Mar, S.A. Résumé des fondamentaux
| PHM statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €1.36b |
| Bénéfices(TTM) | €56.13m |
| Recettes(TTM) | €218.64m |
Le site PHM est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PHM compte de résultat (TTM) | |
|---|---|
| Recettes | €218.64m |
| Coût des recettes | €14.47m |
| Marge brute | €204.17m |
| Autres dépenses | €148.05m |
| Les revenus | €56.13m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 3.24 |
| Marge brute | 93.38% |
| Marge bénéficiaire nette | 25.67% |
| Ratio dettes/capitaux propres | 17.2% |
Quelles ont été les performances à long terme de PHM?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/09 18:40 |
| Cours de l'action en fin de journée | 2026/08/07 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Pharma Mar, S.A. est couverte par 12 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |